Y-mAbs Therapeutics (YMAB, Financial) has been downgraded from a Neutral to an Underperform rating by BofA analyst Alec Stranahan. The price target for the company's stock has been significantly reduced from $12 to $3. This adjustment comes as the firm anticipates ongoing challenges for the rollout of Danyelza, a treatment aimed at high-risk neuroblastoma.
The analyst highlights the need for further efforts in optimizing the dose of GD2-SADA, a therapy for solid tumors. Additionally, concerns have been raised about the company's current cash reserves, which may not be sufficient, suggesting a potential funding shortfall.
As Y-mAbs Therapeutics navigates these hurdles, the firm and investors remain focused on overcoming these obstacles to stabilize its financial standing and enhance its product offerings.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Y-mAbs Therapeutics Inc (YMAB, Financial) is $16.64 with a high estimate of $26.00 and a low estimate of $7.00. The average target implies an upside of 245.15% from the current price of $4.82. More detailed estimate data can be found on the Y-mAbs Therapeutics Inc (YMAB) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Y-mAbs Therapeutics Inc's (YMAB, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Y-mAbs Therapeutics Inc (YMAB, Financial) in one year is $11.73, suggesting a upside of 143.36% from the current price of $4.82. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Y-mAbs Therapeutics Inc (YMAB) Summary page.
